NCOR1 and hepatocellular carcinoma: Similarly, HBX positive HCC cells Snu423 or Snu398 treated with anti-NCoR siRNA for 48 h also displayed significant reduction in growth (Figure 8B) along with 40–45% reduction in the number of live cells when compared to HBX negative cells HepG2 (Figures 8C,D), suggesting that misfolded NCoR was somehow linked to the growth and survival of HBX positive HCC cells.